NIST just revealed that technology built to sniff out explosives after the attacks became the foundation for THC breath research. Meanwhile California is forcing dispensaries to show you the lab report, and Massachusetts voters are rejecting repeal 71 to 24.
After September 11, law enforcement leaned hard on dogs to detect explosives, but explosives evolve faster than dogs can be retrained. So a NIST researcher named Tara Lovestead built a lab technique to separate and identify compounds suspended in air, essentially trying to replicate what a bomb-sniffing dog does. Twenty-five years later, NIST says that work became the foundation for marijuana breathalyzer research.
That’s the kind of story that tells you where cannabis actually is right now. Not fighting for the right to exist, but working on the hard technical problems that come after.
Look at the rest of today’s feed. Gavin Newsom signed a law requiring retailers to hand over a product’s lab certificate when a customer asks. North Carolina has to decide whether to regulate a $3.2 billion hemp beverage industry or effectively ban it. Oregon discovered it can price its own psilocybin market out of existence. Pennsylvania may be three Senate seats from legalization. Massachusetts voters look unwilling to give legalization back. A Nebraska candidate is running an attack ad built from his opponent’s old anti-marijuana quote. And state regulators are telling the DEA that Schedule III won’t work if Washington won’t coordinate.
The theme running through all of it is credibility. Can consumers trust the lab? Can police trust the impairment test? Can businesses trust regulators not to price them out? Can states trust the DEA? Legalization answers whether cannabis is permitted. This stuff answers whether the system around it deserves anyone’s confidence. Let me walk you through it.
California is making dispensaries show you the lab report.
Newsom signed two bills Sunday covering marijuana testing, laboratory performance, track-and-trace data, hemp rules, and consumer access. The most important is AB 1965, which requires retailers to provide a product’s certificate of analysis when a consumer asks for it. That certificate is the lab report, showing which cannabinoids are present and whether testing found contaminants. The law also makes explicit that products offered for sale can be tested or retested, and lets the Department of Cannabis Control buy products directly off the market for independent analysis.
This matters because cannabis testing has a credibility problem, and the incentives behind it are not subtle.
Put two jars side by side, one labeled 24% THC and one labeled 31%. Most consumers reach for the second. That creates pressure through the entire supply chain, and whenever the party being tested picks and pays the tester, you need safeguards.
That’s lab shopping, and California’s new law goes at it directly by requiring testing laboratories to participate in performance programs designed to check whether results stay consistent across labs, including blind proficiency testing and round-robin exercises where multiple labs test comparable samples and regulators compare. If the same product produces wildly different numbers depending on who tests it, the whole regulated system loses credibility. Newsom also signed AB 2250, expanding track-and-trace across cultivation, harvesting, processing, manufacturing, distribution, inventory, sales, and delivery, while removing isolated CBN from the definition of cannabis concentrate. For lenders and insurers, stronger testing is quietly good news, because product quality is operational risk, and a contaminated product means recalls, lawsuits, lost inventory, penalties, and brand damage. If you’re financing a manufacturer producing millions in gummies or vapes, the lab system protecting those products is part of your borrower’s risk environment. One suggestion for operators: a 12-page PDF full of scientific abbreviations technically provides information without providing useful information. Translate it. Potency, major cannabinoids, contaminant results, test date, batch number, lab identity.
The bottom line: California is moving from “trust the label” to “prove the label.” Good operators shouldn’t fear lab accountability, because when unreliable testing damages consumer confidence, every legitimate company pays for it.
The THC breathalyzer problem is harder than everyone assumes.
NIST highlighted the bomb-detection connection during National Forensic Science Week, explaining how Lovestead’s headspace technique, built to identify compounds suspended in air, became foundational to marijuana breath research. She described the THC breath work as one of the most difficult measurement challenges of her career, and the agency reported last year that scientists achieved the first detection of THC in human breath after consumption of cannabis-infused edibles.
Here’s why this is so hard, and why it matters more than most legalization debates.
Alcohol dissolves readily in blood and correlates decently with breath concentration. THC is fat-soluble and can stay detectable long after the effect is gone. A frequent consumer might test positive while completely sober.
So detecting THC isn’t enough. A useful roadside device has to answer a much harder question: is this person impaired right now? NIST notes THC is a heavy compound and difficult to measure in breath, and the smell people associate with marijuana isn’t THC at all, it’s volatile aromatic compounds that tell police nothing about intoxication. The policy stakes are enormous, because impaired driving remains one of the legitimately strong concerns opponents raise, and without a way to distinguish someone who consumed yesterday from someone who’s unsafe right now, enforcement gets unfair fast, creating problems for drivers, police, prosecutors, employers, insurers, and courts. But regulators should resist rushing immature technology into enforcement, since false positives would destroy public confidence and false negatives would undermine safety. Any device needs validation across consumption methods, body types, frequent versus occasional users, edibles versus inhaled, different concentrations, and time since use.
The bottom line: Cannabis has been waiting for its breathalyzer and we’re not there yet, but the science is advancing. Legalization creates problems politics can’t solve. Sometimes you need measurement science.
North Carolina’s hemp drink fight is regulation versus prohibition, nothing else.
North Carolina has accidentally become one of America’s most interesting cannabis beverage laboratories, with no conventional recreational market but hemp THC drinks spreading through bars, restaurants, breweries, distributors, and grocery stores. Now lawmakers have to decide what to do with an industry they already have. Melissa Johnston, VP of strategic development at Tryon Distributing, argues in an op-ed that lawmakers should regulate hemp drinks rather than effectively ban them. The fight centers on HB 328, which legislators delayed until November over concerns it amounts to near-total prohibition.
Her family’s distribution company has operated in North Carolina for 42 years and added its first hemp beverage brand in 2024, and she says the category became one of the strongest parts of the portfolio, driving retailer business and leading them to hire staff and train the sales team on cannabis beverages. A 2026 Whitney Economics study puts North Carolina’s hemp industry around $3.2 billion supporting roughly 16,000 jobs, not counting the hospitality businesses now selling these drinks.
The “hemp loophole” framing is eight years out of date. Congress may have enabled this accidentally in 2018, but we’re not debating a hypothetical anymore. We’re debating operating businesses, employees, inventory, distribution contracts, and shelf space.
You can still think the original framework was badly designed. Changing it now has economic consequences either way. And note what Johnston is actually asking for: 21-plus purchasing, third-party lab testing, clear labeling, consumer protections. That’s not a demand for an unregulated market, it’s an argument that regulation beats prohibition, which increasingly mirrors alcohol. A regulated hemp beverage can have standardized serving sizes, maximum THC content, age verification, tamper-resistant packaging, testing, label disclosures, advertising limits, and taxes. A prohibited one sold underground has none of that. North Carolina has another reason to think carefully, since its cannabis advisory council is separately studying broader marijuana policy including state-operated stores, meaning the state could end up regulating intoxicating cannabis through multiple overlapping systems. Designing those separately without considering how they interact would be a mistake.
The bottom line: North Carolina isn’t deciding whether THC beverages exist, they already do. It’s deciding who supplies them, licensed taxpaying businesses or whatever emerges after prohibition.
Oregon almost taxed its own psilocybin program to death, and its own spreadsheet stopped it.
Oregon’s legal psilocybin program hit a problem cannabis regulators will recognize instantly. The regulator needs money, the businesses don’t have money, so the regulator proposed charging businesses more money, and then its own analysis suggested the businesses might vanish, leaving even less money. The Oregon Health Authority has now abandoned rules that would have roughly doubled annual licensing fees and eliminated discounts for veterans and lower-income participants, after operators warned the increases could push a fragile market over the edge.
The state’s own numbers made it awkward. An internal analysis projected that if higher fees caused enough operators to surrender licenses, the program could face a $4.2 million shortfall this budget cycle. Without the increases, the projected shortfall was about $3.8 million. Even a scenario where license counts held steady despite higher fees still projected a $2.9 million deficit.
Raising fees didn’t fix the funding problem. It made it worse. Every fee becomes part of the legal product’s price, and the legal market is competing against an illicit one that pays no license fees, no testing costs, no compliance staff, and no taxes.
That’s the ceiling on how much regulation a market can economically carry, and Oregon’s model is especially exposed because consumers aren’t just buying psilocybin, they’re buying psilocybin plus facility plus facilitator plus compliance plus administration. The problem didn’t disappear with the fee hike, either, since the program still needs funding and the original ballot campaign assumed licensing revenue would eventually sustain it rather than general-fund subsidies. That assumption deserves reexamination. One alternative reportedly under consideration is raising the 15 percent product tax, which runs into the same loop: higher tax, higher price, lower legal participation. The smarter conversation starts with the cost of regulation itself, asking what the program actually needs, what can be simplified, which functions genuinely protect consumers, and whether society should subsidize part of the infrastructure if these services produce broader mental-health benefits.
The bottom line: A legal market can be regulated so aggressively it stops being viable. The answer isn’t deregulation, it’s sustainable regulation, because when the legal option becomes unaffordable people don’t stop consuming, they stop participating in the system built to protect them.
Pennsylvania legalization is now an arithmetic problem: three Senate seats.
Pennsylvania cannabis has lived in a weird category for years, popular enough to feel inevitable and divided enough to stay impossible. That could change in November. House Speaker Joanna McClinton says Democrats flipping three state Senate seats could create a realistic pathway next year. Democrats already control the House, Governor Shapiro supports adult-use reform, and the Republican-controlled Senate has been the obstacle.
That makes the 2026 legislative elections unusually important, because Pennsylvania isn’t a small emerging market. Nearly 13 million residents, Philadelphia and Pittsburgh, major suburban corridors, an established medical program with existing cultivators and dispensaries, and legal markets on nearly every side in New York, New Jersey, Maryland, and Ohio. Pennsylvania consumers don’t need permission to see what legal cannabis looks like, they can just drive.
A bipartisan Senate proposal has contemplated adults 21 and older possessing up to 30 grams of flower, five grams of concentrate, and 1,000 milligrams of THC in edibles, with expungement provisions, but leadership hasn’t delivered a path to passage.
Don’t treat “legalization” as a single underwriting event. The statute determines the market, licensing determines the borrowers, taxation determines margins, zoning determines real estate, and ownership rules determine capital.
That distinction is especially live in Pennsylvania, where the House previously advanced a state-store model while other lawmakers favor private retail, and those two produce completely different commercial landscapes. Under state retail, capital concentrates around cultivation, processing, equipment, distribution, real estate, and ancillary services. Under private retail, dispensary ownership itself becomes a major lending category. For financial institutions, this is exactly the moment relationship-building matters, because waiting until dispensaries open is late. Prospective operators are already talking to attorneys, accountants, landlords, investors, equipment suppliers, and consultants, and those professional-service relationships usually determine which bank gets the introduction when capital is finally needed. The play isn’t underwriting companies that don’t exist yet. It’s mapping the ecosystem.
The bottom line: Pennsylvania has moved from abstract policy question to electoral arithmetic. Three seats, and 2027 could open one of the largest remaining East Coast markets.
Massachusetts has tried legal weed, and 71% won’t give it back.
A new poll finds 71 percent of likely voters oppose the November initiative that would roll back major parts of the adult-use law, with 24 percent supporting and 5 percent undecided. The proposal wouldn’t fully recriminalize, since adults could still possess and the medical program would continue, but commercial recreational sales would end and home cultivation would be eliminated.
Think about what that produces. Possession stays legal while the primary legal channel supplying recreational consumers disappears. Demand doesn’t vanish, so some people get medical cards, some travel, and others go back to unlicensed sellers. That’s the central weakness of reversing legalization after a market matures. Massachusetts approved recreational in 2016, retail began in 2018, and the state has since passed $10 billion in adult-use sales, meaning repeal now means dismantling businesses, employees, landlords, suppliers, municipal revenue, bank accounts, insurance policies, and professional services.
The partisan breakdown may matter more than the headline, because opposition to rollback runs across Democrats, independents, and Republicans by a wide margin.
A voter doesn’t have to consume cannabis to prefer regulated stores over illicit dealers. Legalization’s political durability doesn’t require enthusiasm for marijuana, just a belief that the alternative is worse.
The campaign is nationally significant either way. If opponents can roll back an established market, copycat campaigns appear elsewhere. If voters reject repeal by anything close to 71-24, the lesson runs the other direction, and going backward becomes much harder than prohibition advocates assume. That matters to capital, because businesses make long-term investments only when they believe the regulatory system survives. Banks lend against cash flow, landlords sign leases, investors fund expansion, and political durability removes one whole category of uncertainty from all of it.
The bottom line: The next milestone isn’t another state voting yes. It’s an existing legal state being asked whether it wants prohibition back, and Massachusetts is answering no. Regulated cannabis is becoming politically sticky.
A Nebraska candidate is attacking his opponent with an anti-marijuana quote.
Five years ago, then-Governor Pete Ricketts warned that legalization would “kill your kids.” In 2026, Independent Senate candidate Dan Osborn released an ad highlighting that statement as evidence Ricketts is out of step with voters on cannabis.
The reversal deserves more attention than the ad. For decades, candidates worried about looking soft on marijuana, and reformers played defense. Osborn apparently believes opposition to cannabis reform is now the position requiring explanation. Part of that comes from voters directly, since Nebraska approved medical marijuana measures in 2024, so Ricketts isn’t opposing a hypothetical, he’s positioned against something the electorate approved.
The question shifts from “do you personally like marijuana?” to “should elected officials respect what voters decided?” Those are very different political arguments, and the second one is much harder to lose.
Ricketts remains one of Congress’s more outspoken opponents, having criticized federal rescheduling, opposed banking legislation, and supported keeping federal tax disadvantages for marijuana businesses even under a less restrictive schedule, which gives Osborn a record to contrast against. The changing data makes old rhetoric harder to defend too, since recent federal and state surveys show teenage marijuana use declining rather than exploding as legalization expands. That doesn’t mean marijuana is safe for adolescents, it isn’t. But claims that adult legalization inevitably produces catastrophic youth outcomes are now testable against a decade of evidence from legal states covering tax revenue, youth consumption, crime, public health, and enforcement, which makes hyperbole vulnerable in a way it never used to be. Nebraska matters federally too, since a senator influences banking legislation, hemp regulation, 280E, veterans access, research, and scheduling oversight.
The bottom line: The striking part isn’t that a politician said something extreme about marijuana. It’s that another politician thinks showing voters that quote helps him win. In parts of America, uncompromising prohibition may now be the riskier position.
State regulators to the DEA: if Schedule III runs on our systems, talk to us.
Washington is attempting something unprecedented, moving qualifying medical marijuana into a less restrictive schedule while relying heavily on state cannabis systems it didn’t design. That requires coordination, and state regulators say they aren’t getting enough. In a Marijuana Moment op-ed, Gillian Schauer of the Cannabis Regulators Association argues DEA headquarters needs to work far more closely with state officials during implementation.
The problem is structural. For decades the federal government prohibited cannabis, states built medical programs anyway, and each wrote its own rules on patients, caregivers, cultivation, testing, manufacturing, dispensing, tracking, product limits, and physician participation. Those systems were never designed as branches of a federal framework, and now they matter federally without fitting together.
Take something basic, like who can pick up the medicine. Federal rules may contemplate dispensing directly to a patient. State systems often allow caregivers to purchase or transport for patients who can’t easily visit. Which standard applies? That sounds small until an inspector walks in. Then it’s compliance.
Regional DEA offices have reportedly engaged with regulators in some places, but the concern is inconsistent headquarters-level coordination. That should concern lenders, because Schedule III usually gets discussed purely as a 280E tax event, and moving qualifying activity out from under it can turn ugly cash flow into strong cash flow by restoring deductions for payroll, rent, marketing, administrative expenses, and professional fees. But don’t model only the upside. If a borrower’s improved economics depend on qualifying for federal treatment, you need to understand what keeps that qualification intact, which means future underwriting increasingly includes whether the business is federally registered, whether the DEA has inspected it, whether deficiencies were identified, how management documents medical sales, how the borrower is treating 280E, and what happens financially if eligibility changes. Those are exactly the questions banks ask healthcare, pharmaceutical, and government-contracting borrowers every day.
The bottom line: Schedule III isn’t finished when someone changes a line in the Controlled Substances Act. America’s next cannabis problem may not be prohibition. It may be regulatory interoperability.
Tuesday closing
For most of marijuana’s political history, everyone argued from predictions. Supporters predicted regulation would beat prohibition, opponents predicted disaster, businesses predicted enormous markets, governments predicted enormous revenue. Everyone had a model. Nobody had much evidence.
That era is ending, and today’s stories show what replaces it. California can look at a decade of legal cannabis and conclude testing needs improvement, so improve it, consumers need transparency, so hand them the certificate, labs need accountability, so test the testers. NIST can acknowledge that detecting impairment is genuinely hard and build better measurement instead of pretending a blood THC number works like blood alcohol. North Carolina can acknowledge a real market already exists and debate how to govern existing demand rather than pretending the choice is between THC beverages and a THC-free world. Oregon can run its own numbers and discover a regulation meant to stabilize the system might destabilize it. Massachusetts voters can evaluate legalization after living with it instead of guessing.
The industry should embrace that, because evidence cuts both ways. If labs produce unreliable results, fix them. If taxes push consumers toward illicit markets, lower them. If youth use rises somewhere, investigate it. If a product is unsafe, recall it. If Schedule III improves cash flow, measure it, and measure the new compliance costs too. Legalization shouldn’t become a religion any more than prohibition should. And the breathalyzer story is the right metaphor for all of it, because politicians have wanted a simple cannabis impairment number for years and science keeps answering that it’s more complicated than that. Good policy doesn’t respond by inventing certainty. It builds better measurement.
Cannabis lending should follow the same philosophy. The old question was whether an institution banks cannabis. The better questions are whether this is a good business, whether the financials are reliable, whether management is credible, whether taxes are current, whether testing is trustworthy, whether insurance is adequate, whether inventory is controlled, and whether the business survives price compression. A mature industry shouldn’t ask to be protected from ordinary commercial scrutiny, it should want the chance to pass it. That’s where California’s testing rules ultimately point, because trust isn’t created by calling something regulated, it comes from proving the regulation works. And that runs both directions. States can’t demand millions in compliance spending while administering licensing through opaque systems. Washington can’t lean on state medical programs and refuse to coordinate with the regulators running them. Cannabis spent decades asking whether America would let it exist, and that question is going obsolete. The harder one now is whether the industry can prove the system works, and for the first time there’s enough history, science, and data to actually answer it.
That’s what this newsletter is for.
What’s the biggest regulatory challenge your operation is facing right now? Hit reply, I read every response and it shapes what I cover next week.
If this was useful, forward it to someone in the cannabis space or hit the restack button on Substack. It’s how this community grows.